Implantica publishes Interim Report Q2 2022
Executing on RefluxStop™ Commercialisation StrategySignificant events in the second quarter of 2022 · Implantica has completed the first AppetiteControl™ food sensor clinical trial on 20 human volunteers. The results are currently being evaluated. · Implantica successfully conducted its first User Meeting with 11 highly experienced anti-reflux Key Opinion Leaders (KOLs) participating, from several European countries. The purpose of the meeting was to standardize the surgical technique for the RefluxStop™ procedure. A consensus paper has been written and will be published. ·